References
- Smith EL. Abraham White 1908-1980. A biographical memoir. Washington D.C.: National Academy of Sciences; 1985. p. 513.
- Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta 4 accelerates wound healing. J Invest Dermatol. 1999 Sep;113(3):364–368.
- Malinda KM, Goldstein AL, Kleinman HK. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J. 1997 May;11(6):474–481.
- Sosne G, Chan CC, Thai K, et al. Thymosin beta 4 promotes corneal wound healing and modulates inflammatory mediators in vivo. Exp Eye Res. 2001 May;72(5):605–608.
- Sosne G, Szliter EA, Barrett R, et al. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res. 2002 Feb;74(2):293–299.
- Sosne G, Xu L, Prach L, et al. Thymosin beta 4 stimulates laminin-5 production independent of TGF-beta. Exp Cell Res. 2004 Feb 1;293(1):175–183.
- Sosne G, Qiu P, Christopherson PL, et al. Thymosin beta 4 suppression of corneal NFκB: a potential anti-inflammatory pathway. Exp Eye Res. 2007 Apr;84(4):663–669.
- Qiu P, Wheater MK, Qiu Y, et al. Thymosin beta4 inhibits TNF-alpha-induced NF-kappaB activation, IL-8 expression, and the sensitizing effects by its partners PINCH-1 and ILK. FASEB J. 2011 Jun;25(6):1815–1826.
- Dunn SP, Heidemann DG, Chow CY, et al. Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta 4. Arch Ophthalmol. 2010 May;128(5):636–638.
- Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015 May;34(5):491–496.
- Belmonte C. Eye dryness sensations after refractive surgery: impaired tear secretion or “phantom” cornea? J Refract Surg. 2007;23(6):598–602.
- Rosenthal P, Baran I, Jacobs DS. Corneal pain without stain: is it real? Ocul Surf. 2009;7(1):28–40.
- Rosenthal P, Borsook D. The corneal pain system. Part I: the missing piece of the dry eye puzzle. Ocul Surf. 2012;10(1):2–14.
- Crane AM, Levitt RC, Felix ER, et al. Patients with more severe symptoms of neuropathic ocular pain report more frequent and severe chronic overlapping pain conditions and psychiatric disease. Br J Ophthalmol. 2016;101(2):227–231.
- Galor A, Covington D, Levitt AE, et al. Neuropathic ocular pain due to dry eye is associated with multiple comorbid chronic pain syndromes. J Pain. 2016;17(3):310–318.
- Rosenthal P, Borsook D, Moulton EA. Oculofacial pain: corneal nerve damage leading to pain beyond the eye. Invest Ophthalmol Vis Sci. 2016;57(13):5285–5287.
- Rosenthal P, Borsook D. Ocular neuropathic pain. Br J Ophthalmol. 2016;100(1):128–134.
- Theophanous C, Jacobs DS, Hamrah P. Corneal neuralgia after LASIK. Optom Vis Sci. 2015;92(9):e233–e240.
- Galor A, Levitt RC, Felix ER, et al. Neuropathic ocular pain: an important yet under evaluated feature of dry eye. Eye (Lond). 2015;29(3):301–312.
- Sosne G, Hafeez S, Greenberry AL 2nd, et al. Thymosin beta4 promotes human conjunctival epithelial cell migration. Curr Eye Res. 2002 Apr;24(4):268–273.
- Sosne G, Siddiqi A, Kurpakus-Wheater M. Thymosin-beta4 inhibits corneal epithelial cell apoptosis after ethanol exposure in vitro. Invest Ophthalmol Vis Sci. 2004 Apr;45(4):1095–1100.
- Sosne G, Albeiruti AR, Hollis B, et al. Thymosin beta4 inhibits benzalkonium chloride-mediated apoptosis in corneal and conjunctival epithelial cells in vitro. Exp Eye Res. 2006 Sep;83(3):502–507. Epub 2006 Apr 21.
- Sosne G, Christopherson PL, Barrett RP, et al. Thymosin-beta4 modulates corneal matrix metalloproteinase levels and polymorphonuclear cell infiltration after alkali injury. Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2388–2395.
- Saghizadeh M, Kramerov AA, Tajbakhsh J, et al. Proteinase and growth factor alterations revealed by gene microarray analysis of human diabetic corneas. Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3604–3615.
- Sosne G, Qiu P, Kurpakus-Wheater M. Thymosin beta-4 and the eye: I can see clearly now the pain is gone. Ann N Y Acad Sci. 2007 Sep;1112:114–122.
- Dunn SP, Heidemann DG, Chow CY, et al. Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta4. Ann N Y Acad Sci. 2010 Apr;1194:199–206.
- Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. Clin Ophthalmol. 2015 May 20;9:877–884.
- Sosne G, Rimmer D, Kleinman HK, et al. Thymosin beta 4: a potential novel therapy for neurotrophic keratopathy, dry eye, and ocular surface diseases. Vitam Horm. 2016;102:277–306.